Pazopanib, Multi-receptor tyrosine kinase inhibitor (TBI2158)

Description

Product Details

Formal Name: 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide

Alternate Names: GSK-VEG10003; GW786034B

Molecular Formula: C₂₁H₂₃N₇O₂S

Formula Weight: 437.50

CAS Number: 444731-52-6

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 16 mg/ml).

Storage: -20°C

Stability: ≥ 1 year.

Applications

Multi-receptor tyrosine kinase inhibitor

Functions

Inhibits multiple receptor tyrosine kinases including VEGFR1,2 and 3 (IC50s=10, 30, 47 nM respectively) and PDGFRα, β and c-Kit (IC50s=71, 84, 74 nM respectively) and others such as FGFR. The drug targets both the tumor and endothelial cells in a mouse xenograft model of human multiple myeloma. It reduces joint pain and inhibits cartilage degeneration in rodent osteoarthritis models. VEGF inhibitors such as pazopanib have potential for treatment of neovascular age-related macular degeneration. In clinical use for renal cell carcinoma.

Application Procedures

First dissolved in DMSO (up to 16 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.